GO
Loading...

AstraZeneca PLC

More

  • May 5- Pfizer Inc, the biggest U.S. drugmaker, on Monday reported revenues well below Wall Street expectations, hurt by falling sales of generic medicines it calls established pharmaceuticals. Pfizer, which is trying to take over Britain's AstraZeneca Plc, earned $2.33 billion, or 36 cents per share, in the first quarter ended March 31.

  • UK politicians weigh in on Pfizer's AstraZeneca bid Monday, 5 May 2014 | 2:38 AM ET

    Britain's opposition Labour party has called for an inquiry into a potential takeover of British firm AstraZeneca by U.S. drugmaker Pfizer.

  • France's Sanofi and U.S. drugmakers Merck& Co and Abbott Laboratories are exploring selling off their mature drugs that have lost patent protection, Reuters reported this week, citing people familiar with the plans.

  • LONDON, May 4- Britain should conduct an independent assessment of a potential takeover of British pharmaceutical firm AstraZeneca by U.S. drugmaker Pfizer, opposition Labour party leader Ed Miliband said on Sunday. AstraZeneca rejected a 63 billion pound takeover bid from Pfizer on Friday, but the U.S. firm is expected to pursue its interest.

  • LONDON, May 4- Britain should conduct an independent assessment of a potential takeover of British pharmaceutical firm AstraZeneca by U.S. drugmaker Pfizer, the leader of the opposition Labour party Ed Miliband said on Sunday.

  • Employees at Pfizer Inc's U.S. research centers may want to dust off their resumes if the company's proposed acquisition of Britain's AstraZeneca comes to fruition.

  • May 3- Pfizer Inc has already had its takeover overtures rebuffed three times by rival AstraZeneca Plc, but investors in the U.S. drugmaker say it can tolerate a little more rejection before going hostile with the deal.

  • NEW YORK, May 3- Employees at Pfizer Inc's U.S. research centers, such as the La Jolla, California site that specializes in cancer drugs, may want to dust off their resumes if the company's proposed acquisition of Britain's AstraZeneca comes to fruition.

  • *AstraZeneca rejects Pfizer's raised bid of $106 bln. NEW YORK, May 2- U.S. stocks eased on Friday as an upbeat jobs report was offset by concerns about more violence in Ukraine.

  • Astrazenaca has rejected Pfizer's $106 billion bid for the company. CNBC's Meg Tirrell, and Tim Chiang, CRT Capital senior analyst, discuss Pfizer's "opportunistic" strategy, and m&a in the pharma industry.

  • *AstraZeneca rejects Pfizer's raised bid of $106 bln. Yet on the results front, LinkedIn Corp shares dropped 6.9 percent to $150.06, a day after the social networking company forecast 2014 revenue below Wall Street's expectations, the latest company to disappoint on sales this reporting period.

  • European stocks dip as investors book recent gains Friday, 2 May 2014 | 12:40 PM ET

    *Deutsche Telekom, Bouygues, Iliad up on M&A talk. Mergers and acquisitions continued to boost a number of sectors, with Deutsche Telekom up 1.1 percent on talk that Sprint Corp has approached banks to work out funding for its bid for T-Mobile US Inc, which is majority-owned by the German telecom operator.

  • *Astrazeneca rejects Pfizer's raised bid of $106 bln. While the report provided an encouraging read on the labor market, many market participants said Wall Street's gains over the week made further advances unlikely.

  • LONDON, May 2- U.S. drugmaker Pfizer Inc's effort to sweeten its bid for Britain's AstraZenaca Plc with commitments on research, manufacturing and jobs is claimed as a coup by the UK government, but many are deeply sceptical.

  • M&A helps keep European stock rally alive Friday, 2 May 2014 | 10:59 AM ET

    *Deutsche Telekom, Bouygues, Iliad up on M&A talk. Deutsche Telekom was the top gainer among European blue-chips. It rose 1.9 percent on talk Sprint Corp has approached banks to work out funding for its bid for T-Mobile US Inc, which is majority-owned by the German telecom operator.

  • *Astrazeneca rejects Pfizer's raised bid of $106 bln. The payrolls gain of 288,000 was the largest since January 2012 and beat Wall Street's expectations for an increase of just 210,000..

  • Pfizer $106.5B offer ‘inadequate’: AstraZeneca Friday, 2 May 2014 | 9:23 AM ET
    Pfizer

    AstraZeneca's board rejected a $106.5 billion bid from predator Pfizer just hours after it was received, arguing that it is too low.

  • AstraZeneca rejects new Pfizer bid     Friday, 2 May 2014 | 9:07 AM ET

    AstraZeneca has rejected Pfizer's sweetened bid claiming it undervalues the company. The "Squawk on the Street" news team shares their thoughts on the latest bid and the U.S. tax code.

  • U.S. stock index futures pointed to a slightly higher open on Wall Street, ahead of the government’s all-important non-farm payrolls jobs report.

  • LONDON, May 2- Britain's government said it was considering whether reassurances made by Pfizer over its potential takeover of AstraZeneca offered sufficient protection to maintain the country's life sciences sector and related jobs.